On Tuesday, Avid Bioservices Inc (CDMO) stock saw a decline, ending the day at $12.23 which represents a decrease of $-0.02 or -0.16% from the prior close of $12.25. The stock opened at $12.25 and ...

Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move ...

Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

According to Avid's CFO, as revenue increases, incremental EBITDA is expected to drop through at an ~50% rate, which is not adequately captured in the transaction price.

Avid Bioservices shares were up 12% at $12.25 after getting a buyout offer from GHO Capital Partners and Ampersand Capital Partners. Under the terms of the buyout, Avid will be acquired by funds ...

Avid Bioservices Inc., a Tustin-based biotech company, agreed to go private in an $850-million deal that values the company ...

Upon the completion of the merger, each share of Avid Bioservices’ common stock will be converted into the right to receive $12.50 in cash, without interest. Additionally, outstanding options ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

The $12.50-per-share takeover has been approved by Avid's board and is scheduled to close in the first quarter of 2025, ...